Home › Funds › Livforsakringsbolaget Skandia, Omsesidigt › EXEL

Livforsakringsbolaget Skandia, Omsesidigt position in EXEL

EXELIXIS INC · Health Care

Livforsakringsbolaget Skandia, Omsesidigt reported holding 269,603 shares of EXEL (EXELIXIS INC) in its Q3 2026 13F filing — a position valued at US$22.2M, representing 0.73% of its reported portfolio and ranking #32 among its reported holdings. Livforsakringsbolaget Skandia, Omsesidigt has disclosed EXEL holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)269.60K sh
Reported value held$22.16M
Portfolio Weight0.73%
First reportedQ2 2025
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Livforsakringsbolaget Skandia, Omsesidigt's EXEL position evolved

Livforsakringsbolaget Skandia, Omsesidigt first disclosed a stake in EXEL in Q2 2025 at 78,100 shares (US$3.4M). The position peaked in Q2 2026 at 293,703 shares, worth US$26.5M. Across 6 filings, Livforsakringsbolaget Skandia, Omsesidigt increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 269,603 shares valued at US$22.2M — a reduction of -24,100 shares quarter over quarter.. Notable position changes include a 31% increase in Q3 2025 (shares rose 7% over the following quarter), a 184% increase in Q4 2025 (shares fell 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 78.10K $3.44M New
Q3 2025 102.65K $6.05M Add
Q4 2025 291.35K $19.63M Add
Q1 2026 241.10K $15.57M Reduce
Q2 2026 293.70K $26.50M Add
Q3 2026 269.60K $22.16M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EXEL and 13F data

EXEL (EXELIXIS INC) is a Health Care company. 41 other funds we track also report a position in EXEL — the largest reported positions include Renaissance Technologies (US$747.2M), Farallon Capital Management (US$732.8M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$732.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EXEL

All EXEL fund holders →

FAQ

How long has Livforsakringsbolaget Skandia, Omsesidigt held EXEL?

Livforsakringsbolaget Skandia, Omsesidigt has disclosed EXEL holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is Livforsakringsbolaget Skandia, Omsesidigt's current position in EXEL?

As of Q3 2026, Livforsakringsbolaget Skandia, Omsesidigt holds 269.60K shares of EXEL (EXELIXIS INC), valued at $22.16M, representing 0.73% of its reported portfolio and ranking #32.

Has Livforsakringsbolaget Skandia, Omsesidigt been buying or selling EXEL?

In the latest 13F filing (Q3 2026), Livforsakringsbolaget Skandia, Omsesidigt reduced its position in EXEL. The position peaked in Q2 2026 at 293.70K shares.

Which other funds hold EXEL?

Other major institutional holders of EXEL include Renaissance Technologies, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.